{"uri": "eng-9430077", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Moderna", "type": "org", "score": 100, "label": {"eng": "Moderna"}}, {"uri": "http://en.wikipedia.org/wiki/Influenza", "type": "wiki", "score": 69, "label": {"eng": "Influenza"}}, {"uri": "http://en.wikipedia.org/wiki/Vaccine", "type": "wiki", "score": 69, "label": {"eng": "Vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/MRNA_vaccine", "type": "wiki", "score": 52, "label": {"eng": "MRNA vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Health_technology", "type": "wiki", "score": 52, "label": {"eng": "Health technology"}}, {"uri": "http://en.wikipedia.org/wiki/Respiratory_disease", "type": "wiki", "score": 52, "label": {"eng": "Respiratory disease"}}, {"uri": "http://en.wikipedia.org/wiki/Messenger_RNA", "type": "wiki", "score": 48, "label": {"eng": "Messenger RNA"}}, {"uri": "http://en.wikipedia.org/wiki/Health", "type": "wiki", "score": 43, "label": {"eng": "Health"}}, {"uri": "http://en.wikipedia.org/wiki/Doctor_of_Philosophy", "type": "wiki", "score": 41, "label": {"eng": "Doctor of Philosophy"}}, {"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer", "type": "wiki", "score": 41, "label": {"eng": "Chief executive officer"}}, {"uri": "http://en.wikipedia.org/wiki/Nasdaq", "type": "wiki", "score": 32, "label": {"eng": "Nasdaq"}}, {"uri": "http://en.wikipedia.org/wiki/St\u00e9phane_Bancel", "type": "person", "score": 27, "label": {"eng": "St\u00e9phane Bancel"}}, {"uri": "http://en.wikipedia.org/wiki/Research_and_development", "type": "wiki", "score": 26, "label": {"eng": "Research and development"}}, {"uri": "http://en.wikipedia.org/wiki/Biopharmaceutical", "type": "wiki", "score": 25, "label": {"eng": "Biopharmaceutical"}}, {"uri": "http://en.wikipedia.org/wiki/Pipeline_transport", "type": "wiki", "score": 21, "label": {"eng": "Pipeline transport"}}, {"uri": "http://en.wikipedia.org/wiki/Biological_life_cycle", "type": "wiki", "score": 11, "label": {"eng": "Biological life cycle"}}], "eventDate": "2024-03-27", "totalArticleCount": 9, "title": {"eng": "Blackstone funds Moderna's flu vaccine program with $750 million By Investing.com"}, "summary": {"eng": "NEW YORK - In a significant move within the pharmaceutical industry, Blackstone (NYSE:BX) Life Sciences, part of Blackstone (NYSE:BX), has entered into a funding agreement with biotechnology company Moderna , Inc. (NASDAQ:MRNA). The deal, announced today, will see Blackstone provide up to $750 million to support the development and commercialization of Moderna's influenza vaccine program.\n\nThis collaboration underscores Blackstone's strategy of partnering with leading life sciences companies to a"}, "location": null, "categories": [{"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals", "label": "dmoz/Business/Biotechnology and Pharmaceuticals", "wgt": 100}, {"uri": "dmoz/Business/Opportunities/Inventions", "label": "dmoz/Business/Opportunities/Inventions", "wgt": 100}, {"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals/Consulting", "label": "dmoz/Business/Biotechnology and Pharmaceuticals/Consulting", "wgt": 100}, {"uri": "news/Business", "label": "news/Business", "wgt": 75}], "articleCounts": {"eng": 9}, "sentiment": 0.3333333333333333, "wgt": 449193600, "relevance": 1}